Article
Clinical Neurology
Yolanda Silva Blas, Michael N. Diringer, Benjamin Lo, Jaime Masjuan, Natalia Perez de la Ossa, Matthew Cardinal, Florence Yong, Tong Zhu, Gang Li, Steven Arkin
Summary: This study identified the maximum tolerated dose of PF-05230907 in subjects with acute intracerebral hemorrhage and evaluated its overall safety and tolerability. Thrombotic events were only observed at the highest dose level tested, with the maximum tolerated dose estimated to be 24 µg/kg.
Article
Health Care Sciences & Services
Masahiro Kojima
Summary: This study proposes an adaptive design for early identification of maximum tolerated dose (MTD) in order to accelerate dose-finding trials. The identification of MTD is determined adaptively using Bayesian analysis, leading to a shortened study period.
BMC MEDICAL RESEARCH METHODOLOGY
(2022)
Article
Engineering, Biomedical
Meredith A. Jackson, Shrusti S. Patel, Fang Yu, Matthew A. Cottam, Evan B. Glass, Ella N. Hoogenboezem, R. Brock Fletcher, Bryan R. Dollinger, Prarthana Patil, Danielle D. Liu, Isom B. Kelly, Sean K. Bedingfield, Allyson R. King, Rachel E. Miles, Alyssa M. Hasty, Todd D. Giorgio, Craig L. Duvall
Summary: The study demonstrates that Kupffer cell release of plate activating factor (PAF) is a key determinant of siRNA nanocarrier toxicity, and inhibiting PAFR can increase the tolerated dose of siRNA nanocarriers.
Article
Oncology
David M. Loeb, Ji Won Lee, Daniel A. Morgenstern, Yvan Samson, Anne Uyttebroeck, Chuhl Joo Lyu, An Van Damme, Karsten Nysom, Margaret E. Macy, Alexandra P. Zorzi, Julia Xiong, Petra Pollert, Ingrid Joerg, Yulia Vugmeyster, Mary Ruisi, Hyoung Jin Kang
Summary: In paediatric patients with refractory/relapsed solid tumours, avelumab monotherapy showed a safety profile consistent with previous adult studies, but clinical benefits were limited.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Oncology
John Maher, David M. Davies
Summary: A new approach to treating cancer involves re-programming patient immune cells to express a cancer-detecting receptor called a CAR. While this method has been successful in treating blood cancers, it is more challenging to treat solid tumors. The identification of targets that differentiate cancer cells from healthy cells is a major obstacle. In a review, clinical data on CAR-based immunotherapy against solid tumors expressing 30 different targets were analyzed, and additional candidates for future clinical evaluation were suggested based on pre-clinical data.
Article
Oncology
Matthias A. Fante, Mona Felsenstein, Stephanie Mayer, Michael Gerken, Monika Klinkhammer-Schalke, Wolfgang Herr, Martin Vogelhuber, Albrecht Reichle, Daniel Heudobler
Summary: The TEPIP regimen showed promising results in treating patients with relapsed and refractory aggressive B-cell lymphoma, especially for those who were motivated for therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biology
John Maher, David M. Davies
Summary: Cancer is a leading cause of death and new immune-based therapies show promise for addressing this problem. Using immune white blood cells with added genetic blueprints, known as CAR cells, has been effective in treating blood cancers. However, treating solid tumors, which account for 90% of all cancers, is more challenging. This review surveys the use of CAR cells in clinical trials and highlights the difficulties in identifying targets and ensuring safety.
Article
Oncology
A. Michaelidou, D. Adjogatse, Y. Suh, L. Pike, C. Thomas, O. Woodley, T. Rackely, N. Palaniappan, V. Jayaprakasam, B. Sanchez-Nieto, M. Evans, S. Barrington, M. Lei, T. Guerrero Urbano
Summary: The FiGaRO trial demonstrated the feasibility and safety of using an FDG-PET-based dose-painting technique for delivering a radiotherapy boost to the FDG-avid primary tumor in patients with oropharyngeal cancer. Despite higher than expected late toxicity rates, the results suggest potential improvement in 3-year survival rates for high-risk patients.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Noemie S. Minczeles, Wouter W. de Herder, Mark W. Konijnenberg, Richard A. Feelders, Tessa Brabander, Johannes Hofland
Summary: Peptide receptor radionuclide therapy (PRRT) can cause dose-limiting toxicities (DLTs) of the bone marrow, liver, and kidneys. It is yet unknown whether women and men are equally at risk of these DLTs. This study found that female neuroendocrine tumor patients more often experienced PRRT-induced toxicities of platelets and hemoglobin than males, but this did not lead to a lower cumulative activity.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Nutrition & Dietetics
Susie Youn, Angela Chen, Vincent Ha, Carole Chambers, Dean T. Eurich, Michael McCall, Michael B. Sawyer
Summary: The study found that adjusting nab-paclitaxel doses based on muscle mass can predict the risk of chemotherapy toxicity. Factors like BMI, body surface area, and initial drug doses did not significantly impact toxicity occurrence.
CLINICAL NUTRITION
(2021)
Article
Medicine, Legal
Damien van Berlo, Marjolijn Woutersen, Andre Muller, Marja Pronk, Jelle Vriend, Betty Hakkert
Summary: The concept of the Maximum Tolerated Dose (MTD) was originally introduced for carcinogenicity testing, but has been mistakenly applied to other toxicity endpoints in test guidelines and guidances. This results in tests being performed at doses too low to elicit toxicity, negatively impacting the reliability of studies and causing a waste of experimental animals.
REGULATORY TOXICOLOGY AND PHARMACOLOGY
(2022)
Article
Oncology
Ke Cao, Josephine Yeung, Yasser Arafat, CheukShan Choi, Matthew Y. K. Wei, Steven Chan, Margaret Lee, Paul N. N. Baird, Justin M. C. Yeung
Summary: This study aims to evaluate the effectiveness of body surface area (BSA), two-dimensional and three-dimensional body composition measurements derived from Lumbar 3 vertebra (L3) computed tomography (CT) slices in predicting dose-limiting toxicities (DLT) in colon cancer patients. The results suggest that compared to BSA and two-dimensional body composition measurements, three-dimensional L3 body composition measurements have greater potential in predicting DLT in CRC patients receiving chemotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Toxicology
Jaroslav Pejchal, Petr Jost, Lubica Muckova, Rudolf Andrys, Miroslav Lisa, Jana Zdarova Karasova
Summary: This study focused on the safety and pharmacokinetics of cucurbit[7]uril (CB[7]). The results showed that CB[7] had no cytotoxicity in human renal cells, but non-parenteral administration caused tissue damage to the kidneys.
ARCHIVES OF TOXICOLOGY
(2022)
Article
Oncology
Patrick Schoffski, Jean -Pascal Machiels, Sylvie Rottey, Behbood Sadrolhefazi, Hanny Musa, Kristell Marzin, Ahmad Awada
Summary: BI 894999, a novel oral BET inhibitor, has shown potent antitumour activity in preclinical studies.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Ye Guo, Weijie Zhang, Jieer Ying, Yanqiao Zhang, Yueyin Pan, Wensheng Qiu, Qingxia Fan, Qi Xu, Yue Ma, Gang Wang, Jing Guo, Weiguo Su, Songhua Fan, Panfeng Tan, Yan Wang, Yang Luo, Hui Zhou, Jin Li
Summary: This study investigated the combination of Fruquintinib and sin-tilimab in patients with advanced solid tumors, including metastatic colorectal cancer. The results showed good safety and tolerability in patients during the dose escalation and dose expansion stages, as well as promising preliminary efficacy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Hans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, Timothy Price, Ralf D. Hofheinz, Bernard Nordlinger, Jean-Francois Daisne, Jos Janssens, Baruch Brenner, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian Fauth, Carla V. Hannig, John Zalcberg, Niall Tebbutt, Murielle E. Mauer, Sandrine Marreaud, Manfred P. Lutz, Karin Haustermans
Summary: The PETACC 6 trial investigated the addition of oxaliplatin to preoperative capecitabine-based chemoradiation and postoperative capecitabine in locally advanced rectal cancer, but found no improvement in efficacy and instead noted impaired tolerability and feasibility.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Filippo Pietrantonio, Giovanni Fuca, Daniele Rossini, Hans-Joachim Schmoll, Johanna C. Bendell, Federica Morano, Carlotta Antoniotti, Salvatore Corallo, Beatrice Borelli, Alessandra Raimondi, Federica Marmorino, Monica Niger, Alessandra Boccaccino, Gianluca Masi, Sara Lonardi, Luca Boni, Filippo De Braud, Maria Di Bartolomeo, Alfredo Falcone, Chiara Cremolini
Summary: The study compared FOLFOXIRI-bevacizumab with FOLFOX-panitumumab in left-sided RAS/BRAF wild-type mCRC and found no significant differences in outcomes, but a numerically superior survival outcome with FOLFOXIRI-bevacizumab. Chemotherapy-related adverse events were more frequent in the FOLFOXIRI-bevacizumab group, suggesting that while doublet chemotherapy plus anti-EGFRs remain the preferred treatment option, FOLFOXIRI-bevacizumab is a valuable alternative with potential better outcomes.
Meeting Abstract
Oncology
Josep Tabernero, Axel Grothey, Dirk Arnold, Michel Ducreux, Peter J. O'Dwyer, Maurizio Perdicchio, Alexander Abbas, Meghna Das Thakur, Natsumi Irahara, Anila Tahiri, Hans-Joachim Schmoll, Eric Van Cutsem
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Zhaohui Jin, Jesse G. Dixon, Hiral Parekh, Frank A. Sinicrope, Greg Yothers, Daniel G. Haller, Hans Schmoll, Aimery De Gramont, Rachel Kerr, Julien Taieb, Eric Van Cutsem, Chris Twelves, Leonard B. Saltz, Naohiro Tomita, Takayuki Yoshino, Thierry Andre, Amit Mahipal, Richard M. Goldberg, Thomas J. George, Qian Shi
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Jun Yin, Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont, Eric Van Cutsem, Julien Taieb, Steven R. Alberts, Norman Wolmark, Hans-Joachim Schmoll, Leonard B. Saltz, Thomas J. George, Richard R. M. Goldberg, Rachel Kerr, Sara Lonardi, Takayuki Yoshino, Greg Yothers, Axel Grothey, Thierry Andre, Qian Shi
Summary: The study suggests that 3-year disease-free survival (DFS) can effectively replace 5-year overall survival (OS) as an endpoint in adjuvant chemotherapy colon cancer trials. Data shows that the association between DFS and OS strengthens as the follow-up duration of OS increases.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Zhaohui Jin, Jesse G. Dixon, Jack M. Fiskum, Hiral D. Parekh, Frank A. Sinicrope, Greg Yothers, Carmen J. Allegra, Norman Wolmark, Daniel Haller, Hans-Joachim Schmoll, Aimery de Gramont, Rachel Kerr, Julien Taieb, Eric Van Cutsem, Christopher Tweleves, Michael O'Connell, Leonard B. Saltz, Sotaro Sadahiro, Charles D. Blanke, Naohiro Tomita, Jean-Francois Seitz, Charles Erlichman, Takayuki Yoshino, Takeharu Yamanaka, Silvia Marsoni, Thierry Andre, Amit Mahipal, Richard M. Goldberg, Thomas J. George, Qian Shi
Summary: The study revealed that tumor biology is a more significant prognostic factor than age of onset in predicting the outcome of stage III colon cancer patients in the Adjuvant Colon Cancer ENdpoint database.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Meeting Abstract
Oncology
Zhaohui Jin, Jesse G. Dixon, Joleen M. Hubbard, Cathy Eng, Christopher Hanyoung Lieu, Jack Fiskum, Leonard B. Saltz, Herbert I. Hurwitz, Alan P. Venook, Hans-Joachim Schmoll, Charles S. Fuchs, J. Randolph Randolph Hecht, Chiara Cremolini, Eduardo Diaz-Rubio, Cornelis J. A. Punt, Niall C. Tebbutt, Volker Heinemann, Takayuki Yoshino, Aimery De Gramont, Qian Shi
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Richard M. Goldberg, Richard Adams, Marc Buyse, Cathy Eng, Axel Grothey, Thierry Andre, Alberto F. Sobrero, Stuart M. Lichtman, Al B. Benson, Cornelis J. A. Punt, Tim Maughan, Tomasz Burzykowski, Dirkje Sommeijer, Everardo D. Saad, Qian Shi, Elisabeth Coart, Benoist Chibaudel, Miriam Koopman, Hans-Joachim Schmoll, Takayuki Yoshino, Julien Taieb, Niall C. Tebbutt, John Zalcberg, Josep Tabernero, Eric Van Cutsem, Alastair Matheson, Aimery de Gramont
Summary: Meta-analysis based on individual participant data is a powerful method for synthesizing evidence in clinical cancer research. The ARCAD database is a leader in using this methodology for methodological research, providing valuable insights into endpoint selection and clinical response assessment.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Andres J. M. Ferreri, Kate Cwynarski, Elisa Pulczynski, Christopher P. Fox, Elisabeth Schorb, Claudia Celico, Monica Falautano, Alessandro Nonis, Paul La Rosee, Mascia Binder, Alberto Fabbri, Fiorella Ilariucci, Mauro Krampera, Alexander Roth, Claire Hemmaway, Peter W. Johnson, Kim M. Linton, Tobias Pukrop, Jettes Sonderskov Gorlov, Monica Balzarotti, Georg Hess, Ulrich Keller, Stephan Stilgenbauer, Jense Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Manuela Zanni, Stefan W. Krause, Hans J. Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Lorenz Thurner, Giuseppina Cabras, Elsa Pennese, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jurgen Finke, Antonella Ferranti, Kelly Cozens, Elvira Burger, Nicoletta Ielmini, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus
Summary: This study reported the results of a trial involving 219 HIV-negative adults with primary CNS lymphoma (PCNSL). The results showed that MATRix significantly improves outcome in patients with PCNSL, with a long-term overall survival rate of 21%-56%. Addition of rituximab benefits patients, and the efficacy of whole-brain irradiation and autologous transplantation is comparable. Salvage therapy was ineffective. Importantly, MATRix and ASCT did not increase non-relapse mortality or second tumor incidence, and the side effects differed between WBRT and ASCT.
Meeting Abstract
Oncology
B. Chibaudel, M. Raeisi, T. Andre, G. Yothers, H. Schmoll, J. Bachet, R. Cohen, N. Wolmark, T. Yoshino, R. Goldberg, R. Kerr, S. Lonardi, T. George, E. Shacham-Shmueli, L. Sharara, Q. Shi, A. de Gramont
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
J. Tabernero, A. Grothey, D. Arnold, A. de Gramont, M. Ducreux, P. O'Dwyer, A. Tahiri, F. Gilberg, N. Irahara, H-J Schmoll, E. Van Cutsem
Summary: The addition of atezolizumab to FP/bevacizumab as first-line maintenance treatment after FOLFOX thorn bevacizumab induction did not improve efficacy outcomes for patients with BRAF wild-type metastatic colorectal cancer (mCRC).
Meeting Abstract
Oncology
C. Gallois, Q. Shi, J. Meyers, T. Andre, T. J. Iveson, A. F. Sobrero, S. Alberts, A. de Gramont, J. Meyerhardt, A. F. Shields, T. Georges, H. J. E-V. Schmoll, I. Souglakos, R. Kerr, S. Lonardi, G. Yothers, T. Yoshino, R. Goldberg, J. Taieb, D. Papamichael
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
Romain Cohen, Morteza Raeisi, Greg Yothers, Hans-Joachim Schmoll, Daniel G. Haller, Jean-Baptiste Bachet, Benoist Chibaudel, Norman Wolmark, Takayuki Yoshino, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Thomas J. George, Einat Shacham Shmueli, Lama Sharara, Thierry Andre, Qian Shi, Aimery De Gramont
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Nadine J. McCleary, William S. Harmsen, Ellana Haakenstad, James M. Cleary, Jeffrey A. Meyerhardt, John Zalcberg, Richard Adams, Axel Grothey, Alberto F. Sobrero, Eric Van Cutsem, Richard M. Goldberg, Marc Peeters, Josep Tabernero, Matt Seymour, Leonard B. Saltz, Bruce J. Giantonio, Dirk Arnold, Mace L. Rothenberg, Miriam Koopman, Hans-Joachim Schmoll, Henry C. Pitot, Paulo M. Hoff, Niall Tebbutt, Gianluca Masi, John Souglakos, Carsten Bokemeyer, Volker Heinemann, Takayuki Yoshino, Benoist Chibaudel, Aimery deGramont, Qian Shi, Stuart M. Lichtman
Summary: This study evaluated the time to progression and survival outcomes of second-line therapy for metastatic colorectal cancer in older adults aged 70 years and older compared with younger adults. It found that older adults were less likely to receive second-line therapy, but there was no statistically significant difference in survival outcomes between older and younger adults following second-line therapy.
JNCI CANCER SPECTRUM
(2022)
Article
Oncology
Jun Yin, Shaheenah Dawood, Romain Cohen, Jeff Meyers, John Zalcberg, Takayuki Yoshino, Matthew Seymour, Tim Maughan, Leonard Saltz, Eric Van Cutsem, Alan Venook, Hans-Joachim Schmoll, Richard Goldberg, Paulo Hoff, J. Randolph Hecht, Herbert Hurwitz, Cornelis Punt, Eduard Diaz Rubio, Miriam Koopman, Chiara Cremolini, Volker Heinemann, Christophe Tournigard, Carsten Bokemeyer, Charles Fuchs, Niall Tebbutt, John Souglakos, Jean-Yves Doulliard, Fairooz Kabbinavar, Benoist Chibaudel, Aimery de Gramont, Qian Shi, Axel Grothey, Richard Adams
Summary: The study compared the outcomes of metastatic colorectal cancer patients from different regions in international randomized clinical trials. It found significant differences in overall survival among patients from different regions, with patients from the UK and Ireland showing lower survival rates compared to central Europe, southern Europe, and the USA. Possible factors contributing to this disparity include greater overall population representation, delayed diagnosis, and reduced availability of therapies.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)